<?xml version="1.0" encoding="UTF-8"?>
<p>Tay et al. synthesised and evaluated 
 <italic>N</italic>-[4-(benzothiazole-2yl) phenyl]-2-aryloxyacetamide derivatives for cytotoxicity and anticancer activity against sixty human cancer cell lines derived from 9 neoplastic diseases, among which L (leukaemia), M (melanoma), RC (renal cancer) NSCLC (non-small cell lung cancer) CC (colon cancer), OC (ovar ian cancer), BC (breast cancer), CNSC (central nervous system cancer) and PC (prostate cancer). Derivatives 
 <bold>49</bold> (
 <italic>N</italic>-(4-(benzo[d]thiazol-2-yl)-3-methoxyphenyl)-3–(4-chlorophenyl)propanamide) and 
 <bold>50</bold> (
 <italic>N</italic>-(4-(benzo[d]thiazol-2-yl)-2-chlorophenyl)-2–(4-chlorophenylthio)acetamide) (
 <xref ref-type="fig" rid="F0030">Figure 30</xref>) exhibited interesting anti-cancer activities. The SAR studies investigated that anticancer activities of these compounds were due to the substitutions (methoxy and chloro groups) present in their molecules
 <xref rid="CIT0051" ref-type="bibr">
  <sup>51</sup>
 </xref>.
</p>
